Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02455479 · ClinicalTrials.gov registry record · Phase 1
Safety Study of a Disrupted Adenovirus (Ad) Serotype Cocaine Vaccine for Cocaine-dependent Individuals
A Phase 1 study of Cocaine Dependence, sponsored by Weill Medical College of Cornell University.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 150
- Enrollment target
- 1
- Study location
NCT02455479: Recruiting Phase 1 study of Cocaine Dependence, sponsored by Weill Medical College of Cornell University.
NCT02455479 is a Phase 1 study of Cocaine Dependence that is actively recruiting participants, run by Weill Medical College of Cornell University. The registered enrollment target is 150 participants, below the 295-participant average among 38 other Cocaine Dependence trials with a reported enrollment target (49% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02455479, a Phase 1 study of Cocaine Dependence, is actively recruiting participants, sponsored by Weill Medical College of Cornell University.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 150 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to assess the safety and preliminary efficacy of an anti-cocaine vaccine called dAd5GNE in cocaine-dependent individuals. It uses the concept of a vaccine to treat the neurological effects of cocaine by evoking "immunity" to prevent the effects of cocaine on the brain.
Primary Outcome
The primary endpoint is to establish the safety of dAd5GNE vaccine using general safety parameters, which includes a general assessment.
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL dAd5GNE Vaccine
Study Locations (1)
New York
- WCMC Department of Genetic Medicine - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2012-06-26 |
| Est. Completion | 2027-12 |
| Phase | Phase 1 |
What NCT02455479 shows while recruiting
NCT02455479 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 295-participant average among 38 other Cocaine Dependence trials with a reported enrollment target (49% lower).
The record links to 1 condition, with Cocaine Dependence appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02455479 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT02455479 about?
NCT02455479 is a clinical study titled "Safety Study of a Disrupted Adenovirus (Ad) Serotype Cocaine Vaccine for Cocaine-dependent Individuals". The purpose of this study is to assess the safety and preliminary efficacy of an anti-cocaine vaccine called dAd5GNE in cocaine-dependent individuals. It uses the concept of a vaccine to treat the neurological effects of cocaine by evoking "immunity" to prevent the effects of cocaine on the brain.
What is the current status of trial NCT02455479?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 150 participants. The study started on 2012-06-26. Estimated completion is 2027-12.
What conditions does trial NCT02455479 study?
This clinical trial studies the following conditions: Cocaine Dependence.
What interventions are being tested in trial NCT02455479?
The interventions under investigation include: Placebo (BIOLOGICAL), dAd5GNE Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT02455479?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02455479 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cocaine Dependence
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02455479's enrollment target sits among peer trials
150 11th of 38 higher than 27 of 38 other Cocaine Dependence trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cocaine Dependence trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Glutamate-Glutamine Cycling (VCYC) During Cocaine Abstinence Using 1H-MRS
COMPLETED · Phase 1
-
Complementary Combination Therapy for Cocaine Dependence
COMPLETED · Phase 1
-
Sex Differences in Progesterone Effects on Responses to Stress and Drug Cues
COMPLETED · Phase 1
-
Rivastigmine and Huperzine A as Treatments for Cocaine Dependence
COMPLETED · Phase 1
-
Long Term Maintenance of Drug Abstinence
COMPLETED · Phase 1
-
Caffeine and Cocaine
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI